Parkinson's Disease Therapeutics Pipeline Grant Program

The Parkinson’s Disease Therapeutics Pipeline Program seeks to advance therapeutic development pre-clinically and/or into clinical trials of approaches that address unmet needs of people with Parkinson’s disease, with a clear potential to prevent, halt, or delay disease progression or to lessen the burden of daily symptoms. A unique aspect of the program is its emphasis on promoting clearer paths to commercialization and market access for the Parkinson's community. MJFF focuses on pre-clinical and clinical programs that may slow or prevent disease progression, as well as efforts that address moderate-to-advanced motor or non-motor symptoms not well-managed by current treatments. This includes interventions like pharmacological (small molecules, biologics, gene therapies) and non-pharmacological (surgical approaches, technology-enabled therapeutics, neuromodulation) strategies. Competitive proposals will show a strong therapeutic rationale, patient value, and potential for preclinical to clinical translation, including well-defined strategies for target and mechanism of action, differentiation from existing therapies, translational biomarkers for monitoring, and patient-centered approaches in clinical trials. Funding varies, with potential awards ranging from $250,000 to over $2M, based on the novelty, development stage, and unmet medical need priority, including both direct and indirect costs.